二甲双胍预防糖尿病前期老年人衰弱的随机临床试验原理与设计
该文描述了一项正在进行的安慰剂对照双盲随机临床试验,受试者为65岁以上糖尿病前期老年人,随机接受二甲双胍或安慰剂并随访2年。主要结局为衰弱,次要结局包括躯体功能、炎症、胰岛素敏感性等,计划入组120名完成者。
要点
- 65岁以上糖尿病前期老年人随机接受二甲双胍或安慰剂,随访2年。
- 主要结局为衰弱,次要结局包括躯体功能、炎症和胰岛素敏感性等。
- 排除基线衰弱、糖尿病、痴呆、未治疗抑郁、活动性恶性肿瘤及严重心肺神经疾病者。
核心结论
- 该研究正在评估二甲双胍作为预防糖尿病前期老年人衰弱潜在治疗药物的作用。
研究设计与样本
- 安慰剂对照、双盲随机临床试验,65岁以上糖尿病前期老年人随机接受二甲双胍或安慰剂,随访2年,计划入组120名完成者。
关键数值与推荐
- 糖尿病前期通过2小时口服葡萄糖耐量试验评估,为纳入必需条件。
- 排除标准包括基线衰弱(Fried标准)、糖尿病、痴呆、未治疗抑郁、活动性恶性肿瘤或严重心血管、肺及神经疾病。
- 主要结局为衰弱;次要结局包括躯体功能(Short Physical Performance Battery)、全身及骨骼肌组织炎症、肌肉胰岛素信号、胰岛素敏感性(胰岛素钳夹)、糖耐量(口服葡萄糖耐量试验)和体成分(双能X线吸收法)。
- 受试者每3个月进行安全性评估,每6个月进行衰弱评估(Fried标准)和口服葡萄糖耐量试验,每12或24个月评估次要结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Frailty is a geriatric syndrome that leads to poor health outcomes with aging. Previous studies have demonstrated that insulin resistance and inflammation predict frailty onset. Metformin is a widely used, well-tolerated drug that improves insulin sensitivity and displays anti-inflammatory properties. It is also known to prevent diabetes onset in adults with prediabetes. We hypothesize that metformin in older adults with prediabetes will promote healthy aging and prevent frailty. Here we describe an ongoing placebo-controlled, double-blinded clinical trial of metformin for the prevention of frailty in older adults with prediabetes. METHODS: Older adults aged more than 65 years are randomized to metformin or placebo and are followed for 2 years. Prediabetes, required for inclusion, is assessed by 2-hour oral glucose tolerance test. Exclusion criteria are baseline frailty (Fried criteria), diabetes, dementia, untreated depression, active malignancy, or severe cardiovascular, pulmonary, and neurologic diseases. Primary outcome is frailty; secondary outcomes are physical function (Short Physical Performance Battery), systemic and skeletal muscle tissue inflammation, muscle insulin signaling, insulin sensitivity (insulin clamp), glucose tolerance (oral glucose tolerance test), and body composition (dual-energy x-ray absorptiometry). Subjects are followed every 3 months for safety assessments and every 6 months for frailty assessment (Fried criteria) and oral glucose tolerance test, and every 12 or 24 months for secondary outcomes. Enrollment of 120 subjects (completers) will take place over a 2-year period. CONCLUSION: Metformin is being examined in this study as a potential therapeutic agent to prevent frailty in older adults with prediabetes. Findings from this trial may have future implications for the screening and potential treatment of prediabetes in older patients with metformin for the prevention of frailty.
引用
- Espinoza SE, Musi N, Wang CP, et al. Rationale and Study Design of a Randomized Clinical Trial of Metformin to Prevent Frailty in Older Adults With Prediabetes. J Gerontol A Biol Sci Med Sci. 2020. PMID: 30888034. doi:10.1093/gerona/glz078
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。